Axogen (AXGN) on Monday reported preliminary Q4 revenue of about $59.9 million, up 21.3% from a year earlier.

Analysts surveyed by FactSet are expecting Q4 revenue of $58 million.

The company said the increase was driven by targeting high-potential accounts in extremities and head & neck procedures, wider adoption of its peripheral nerve surgical algorithm, and increased use of Resensation in post-mastectomy breast reconstruction.

As of Dec. 31, Axogen reported cash, cash equivalents, restricted cash, and investments of roughly $45.5 million.

Axogen shares were 1.4% higher in premarket trading.